MOSES SUNDAR RAJ
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- DENVER, NC
- NPI
- 1992707418
- Received
- $132,210 in 193 records, 2019 to 2025
- As principal investigator
- $2,468,843 of research payments to others in 232 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 37 | $33,332 |
| 2024 | General payment | 41 | $23,848 |
| 2023 | General payment | 24 | $17,486 |
| 2022 | General payment | 23 | $18,771 |
| 2021 | General payment | 16 | $13,040 |
| 2020 | General payment | 16 | $9,257 |
| 2019 | General payment | 36 | $16,472 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 20 | $87,391 |
| Consulting Fee | 33 | $30,762 |
| Food and Beverage | 118 | $7,545 |
| Travel and Lodging | 14 | $3,295 |
| Honoraria | 1 | $3,000 |
| Education | 7 | $216 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | SERVIER PHARMACEUTICALS LLC | $24 | Food and Beverage | In-kind items and services | Tibsovo Drug, Oncology | 2025 | |
| 2025-12-16 | GENZYME CORPORATION | $31 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-12-08 | Incyte Corporation | $99 | Education | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | Genentech USA, Inc. | $25 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2025 | |
| 2025-12-02 | TerSera Therapeutics LLC | $24 | Food and Beverage | In-kind items and services | Quzyttir Drug, Acute Care | 2025 | |
| 2025-11-21 | Janssen Biotech, Inc. | $56 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-11-18 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-11-14 | Deciphera Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-11-08 | AVYXA PHARMA, LLC | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-08 | AVYXA PHARMA, LLC | $177 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-08 | AVYXA PHARMA, LLC | $100 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-08 | AVYXA PHARMA, LLC | $89 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-31 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-10-28 | Janssen Biotech, Inc. | $30 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-10-28 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-10-21 | ARRAY BIOPHARMA INC | $22 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2025 | |
| 2025-10-08 | E.R. Squibb & Sons, L.L.C. | $6,370 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-01 | E.R. Squibb & Sons, L.L.C. | $6,370 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-09-18 | E.R. Squibb & Sons, L.L.C. | $124 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-09-10 | E.R. Squibb & Sons, L.L.C. | $114 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-09-10 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-07-21 | E.R. Squibb & Sons, L.L.C. | $1,820 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-12 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-29 | Janssen Biotech, Inc. | $133 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-05-15 | E.R. Squibb & Sons, L.L.C. | $1,820 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-14 | Astellas Pharma US Inc | $2,000 | Consulting Fee | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-04-14 | E.R. Squibb & Sons, L.L.C. | $5 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-04-10 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-04 | Astellas Pharma US Inc | $266 | Travel and Lodging | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-04-04 | Astellas Pharma US Inc | $44 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-04-04 | Astellas Pharma US Inc | $18 | Travel and Lodging | Cash or cash equivalent | Vyloy Drug, Oncology | 2025 | |
| 2025-04-04 | Astellas Pharma US Inc | $12 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-03-25 | E.R. Squibb & Sons, L.L.C. | $6,370 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-03-18 | Pulmonx Corporation | $169 | Food and Beverage | In-kind items and services | CHARTIS CATHETER Device, PULMONOLOGY | 2025 | |
| 2025-03-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,040 | Consulting Fee | Cash or cash equivalent | FRUZAQLA Drug, ONCOLOGY | 2025 | |
| 2025-03-05 | E.R. Squibb & Sons, L.L.C. | $124 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-02-25 | E.R. Squibb & Sons, L.L.C. | $1,820 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2024-12-11 | E.R. Squibb & Sons, L.L.C. | $6,278 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUGTYRO Drug, Oncology | 2024 | |
| 2024-11-21 | AstraZeneca Pharmaceuticals LP | $115 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-07 | E.R. Squibb & Sons, L.L.C. | $804 | Travel and Lodging | Cash or cash equivalent | AUGTYRO Drug, Oncology | 2024 | |
| 2024-11-07 | E.R. Squibb & Sons, L.L.C. | $121 | Food and Beverage | Cash or cash equivalent | AUGTYRO Drug, Oncology | 2024 | |
| 2024-11-05 | E.R. Squibb & Sons, L.L.C. | $3 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-10-24 | E.R. Squibb & Sons, L.L.C. | $7 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-10-22 | AstraZeneca Pharmaceuticals LP | $114 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-10-14 | AstraZeneca Pharmaceuticals LP | $106 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-10 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-09 | E.R. Squibb & Sons, L.L.C. | $5,137 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-09-27 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-18 | E.R. Squibb & Sons, L.L.C. | $100 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-08-06 | E.R. Squibb & Sons, L.L.C. | $5 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-08-06 | E.R. Squibb & Sons, L.L.C. | $3 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-08-01 | AstraZeneca Pharmaceuticals LP | $1,110 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-08-01 | AstraZeneca Pharmaceuticals LP | $1,110 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-07-30 | AstraZeneca Pharmaceuticals LP | $244 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-07-30 | AstraZeneca Pharmaceuticals LP | $13 | Travel and Lodging | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-07-26 | AstraZeneca Pharmaceuticals LP | $244 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-07-26 | AstraZeneca Pharmaceuticals LP | $41 | Food and Beverage | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-07-26 | AstraZeneca Pharmaceuticals LP | $39 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-07-26 | AstraZeneca Pharmaceuticals LP | $13 | Travel and Lodging | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-07-24 | Regeneron Healthcare Solutions, Inc. | $17 | Education | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-07-02 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2024 | |
| 2024-06-26 | AstraZeneca Pharmaceuticals LP | $122 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-06-18 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-13 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-05-22 | AstraZeneca Pharmaceuticals LP | $525 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-05-13 | Iovance Biotherapeutics, Inc. | $120 | Food and Beverage | Cash or cash equivalent | Amtagvi Drug, Oncology | 2024 | |
| 2024-04-25 | Deciphera Pharmaceuticals Inc. | $3,000 | Honoraria | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2024 | |
| 2024-04-25 | Deciphera Pharmaceuticals Inc. | $44 | Travel and Lodging | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2024 | |
| 2024-03-26 | Intuitive Surgical, Inc. | $131 | Food and Beverage | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-03-21 | Inari Medical, Inc. | $195 | Food and Beverage | In-kind items and services | FLOWTRIEVER CATHETER, S Device, VTE | 2024 | |
| 2024-03-06 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-02-26 | E.R. Squibb & Sons, L.L.C. | $4 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-02-20 | E.R. Squibb & Sons, L.L.C. | $1,120 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-14 | Acrotech Biopharma Inc. | $24 | Food and Beverage | In-kind items and services | BELEODAQ Drug, ONCOLOGY | 2024 | |
| 2024-01-29 | Deciphera Pharmaceuticals Inc. | $114 | Food and Beverage | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2024 | |
| 2024-01-29 | Deciphera Pharmaceuticals Inc. | $87 | Food and Beverage | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2024 | |
| 2024-01-18 | Deciphera Pharmaceuticals Inc. | $409 | Travel and Lodging | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2024 | |
| 2024-01-12 | Deciphera Pharmaceuticals Inc. | $150 | Travel and Lodging | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2024 | |
| 2023-12-29 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-19 | E.R. Squibb & Sons, L.L.C. | $5,137 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-12-14 | E.R. Squibb & Sons, L.L.C. | $5 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-11-22 | E.R. Squibb & Sons, L.L.C. | $5,137 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-11-16 | E.R. Squibb & Sons, L.L.C. | $117 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-11-10 | E.R. Squibb & Sons, L.L.C. | $131 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-11-10 | E.R. Squibb & Sons, L.L.C. | $22 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-11-10 | Merck Sharp & Dohme LLC | $19 | Education | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-11-01 | E.R. Squibb & Sons, L.L.C. | $123 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-10-26 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-10-26 | Celgene Corporation | $13 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2023 | |
| 2023-10-25 | AstraZeneca Pharmaceuticals LP | $127 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-17 | E.R. Squibb & Sons, L.L.C. | $5,137 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-09-27 | E.R. Squibb & Sons, L.L.C. | $58 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-06-16 | Medtronic, Inc. | $111 | Food and Beverage | In-kind items and services | ABRE Device, Stents | 2023 | |
| 2023-06-15 | E.R. Squibb & Sons, L.L.C. | $93 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-06-06 | Intera Oncology, Inc | $162 | Food and Beverage | In-kind items and services | Intera 3000 Implantable Pump Device, Oncology | 2023 | |
| 2023-05-24 | AstraZeneca Pharmaceuticals LP | $133 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-23 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | Kyprolis Drug, Oncology | 2023 | |
| 2023-05-10 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2023 | |
| 2023-05-09 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | JEVTANA Drug, Oncology | 2023 | |
| 2023-03-03 | Mirati Therapeutics, Inc. | $115 | Food and Beverage | Cash or cash equivalent | KRAZATI Drug, ONCOLOGY | 2023 | |
| 2023-02-21 | Mirati Therapeutics, Inc. | $42 | Education | In-kind items and services | KRAZATI Drug, ONCOLOGY | 2023 | |
| 2023-01-31 | EMD Serono, Inc. | $121 | Food and Beverage | Cash or cash equivalent | TEPMETKO Drug, Oncology | 2023 | |
| 2022-11-29 | E.R. Squibb & Sons, L.L.C. | $4,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-11-21 | E.R. Squibb & Sons, L.L.C. | $4,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-11-17 | Inari Medical, Inc. | $157 | Food and Beverage | In-kind items and services | FLOWTRIEVER CATHETER, S Device, VTE | 2022 | |
| 2022-11-10 | E.R. Squibb & Sons, L.L.C. | $96 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-11-03 | E.R. Squibb & Sons, L.L.C. | $120 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-09-06 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-15 | Celgene Corporation | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-15 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-15 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-05 | AstraZeneca Pharmaceuticals LP | $4,162 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2022 | |
| 2022-06-01 | Celgene Corporation | $600 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-01 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-05-21 | AstraZeneca Pharmaceuticals LP | $170 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-05-20 | AstraZeneca Pharmaceuticals LP | $623 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-05-20 | AstraZeneca Pharmaceuticals LP | $192 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-05-20 | AstraZeneca Pharmaceuticals LP | $152 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-05-20 | AstraZeneca Pharmaceuticals LP | $50 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-05-20 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-05-20 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-05-20 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-03-30 | Celgene Corporation | $600 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-03-30 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-02-24 | AstraZeneca Pharmaceuticals LP | $102 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2022 | |
| 2021-12-07 | E.R. Squibb & Sons, L.L.C. | $4,505 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-12-06 | Intera Oncology, Inc | $153 | Food and Beverage | In-kind items and services | Intera 3000 Hepatic Artery Infusion Pump Device, Oncology | 2021 | |
| 2021-11-10 | E.R. Squibb & Sons, L.L.C. | $76 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-07-14 | E.R. Squibb & Sons, L.L.C. | $76 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-07-12 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-07-08 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-07-01 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-30 | AstraZeneca Pharmaceuticals LP | $109 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2021 | |
| 2021-06-29 | E.R. Squibb & Sons, L.L.C. | $4,505 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-06-28 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-09 | E.R. Squibb & Sons, L.L.C. | $83 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-05-18 | E.R. Squibb & Sons, L.L.C. | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-05-14 | E.R. Squibb & Sons, L.L.C. | $4 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-05-14 | E.R. Squibb & Sons, L.L.C. | $2 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-03-18 | Acrotech Biopharma Inc. | $13 | Education | In-kind items and services | BELEODAQ Drug, ONCOLOGY | 2021 | |
| 2021-03-18 | E.R. Squibb & Sons, L.L.C. | $11 | Education | In-kind items and services | OPDIVO Biological, Oncology | 2021 | |
| 2020-12-08 | E.R. Squibb & Sons, L.L.C. | $3,505 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-11-18 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | IMFINZI Drug, Oncology | 2020 | |
| 2020-10-21 | E.R. Squibb & Sons, L.L.C. | $117 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-09-03 | AstraZeneca Pharmaceuticals LP | $80 | Food and Beverage | In-kind items and services | IMFINZI Drug, Oncology | 2020 | |
| 2020-07-28 | E.R. Squibb & Sons, L.L.C. | $250 | Consulting Fee | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-06-01 | E.R. Squibb & Sons, L.L.C. | $1,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-03-17 | E.R. Squibb & Sons, L.L.C. | $250 | Consulting Fee | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-03-06 | Novocure Inc. | $129 | Food and Beverage | Cash or cash equivalent | Oncology Device, Optune Lua | 2020 | |
| 2020-03-05 | E.R. Squibb & Sons, L.L.C. | $3,505 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-02-24 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-02-12 | E.R. Squibb & Sons, L.L.C. | $102 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2020-02-10 | Merck Sharp & Dohme LLC | $12 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-02-03 | Genentech USA, Inc. | $12 | Food and Beverage | In-kind items and services | VENCLEXTA Biological, BioOncology | 2020 | |
| 2020-01-30 | AstraZeneca Pharmaceuticals LP | $113 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2020 | |
| 2020-01-13 | Aurobindo Pharma USA, Inc. | $26 | Food and Beverage | Cash or cash equivalent | Beleodaq Drug, Oncology | 2020 | |
| 2020-01-06 | Genentech USA, Inc. | $12 | Food and Beverage | In-kind items and services | Avastin Biological, BioOncology | 2020 | |
| 2019-12-16 | Genentech USA, Inc. | $11 | Food and Beverage | In-kind items and services | VENCLEXTA Biological, BioOncology | 2019 | |
| 2019-12-09 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-12-02 | AstraZeneca Pharmaceuticals LP | $2,800 | Consulting Fee | Cash or cash equivalent | IMFINZI Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-11-13 | AstraZeneca Pharmaceuticals LP | $88 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2019 | |
| 2019-11-11 | E.R. Squibb & Sons, L.L.C. | $3,505 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-11-11 | SEAGEN INC. | $12 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-11-04 | Genentech USA, Inc. | $13 | Food and Beverage | In-kind items and services | GAZYVA Biological, BioOncology | 2019 | |
| 2019-10-23 | E.R. Squibb & Sons, L.L.C. | $96 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-10-21 | Genentech USA, Inc. | $11 | Food and Beverage | In-kind items and services | TECENTRIQ Biological, BioOncology | 2019 | |
| 2019-10-12 | AstraZeneca Pharmaceuticals LP | $43 | Food and Beverage | In-kind items and services | IMFINZI Drug, Oncology | 2019 | |
| 2019-10-12 | AstraZeneca Pharmaceuticals LP | $43 | Food and Beverage | In-kind items and services | IMFINZI Drug, Oncology | 2019 | |
| 2019-10-12 | AstraZeneca Pharmaceuticals LP | $42 | Food and Beverage | In-kind items and services | IMFINZI Drug, Oncology | 2019 | |
| 2019-09-23 | E.R. Squibb & Sons, L.L.C. | $12 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-09-23 | E.R. Squibb & Sons, L.L.C. | $12 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-09-18 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Stivarga Drug, Oncology | 2019 | |
| 2019-08-29 | Bayer Healthcare Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | Stivarga Drug, Oncology | 2019 | |
| 2019-08-19 | Genentech USA, Inc. | $18 | Food and Beverage | In-kind items and services | Avastin Biological, BioOncology | 2019 | |
| 2019-08-08 | Gilead Sciences, Inc. | $39 | Food and Beverage | In-kind items and services | Zydelig Drug, ONC | 2019 | |
| 2019-07-25 | E.R. Squibb & Sons, L.L.C. | $3,505 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-07-17 | E.R. Squibb & Sons, L.L.C. | $124 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-06-17 | Clovis Oncology, Inc. | $12 | Food and Beverage | In-kind items and services | Rubraca Drug, Oncology | 2019 | |
| 2019-06-12 | E.R. Squibb & Sons, L.L.C. | $3,505 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-06-02 | E.R. Squibb & Sons, L.L.C. | $97 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-05-31 | AstraZeneca Pharmaceuticals LP | $91 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-05-31 | Genentech USA, Inc. | $11 | Food and Beverage | In-kind items and services | GAZYVA Biological, BioOncology | 2019 | |
| 2019-05-15 | E.R. Squibb & Sons, L.L.C. | $102 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-05-10 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Stivarga Drug, Oncology | 2019 | |
| 2019-04-29 | SEAGEN INC. | $12 | Education | In-kind items and services | ADCETRIS Biological, Oncology | 2019 | |
| 2019-04-19 | Exelixis Inc. | $1,960 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Cabometyx Drug, Oncology | 2019 | |
| 2019-04-10 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | ALIMTA Drug, Oncology | 2019 | |
| 2019-04-01 | E.R. Squibb & Sons, L.L.C. | $11 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-03-30 | Exelixis Inc. | $34 | Food and Beverage | In-kind items and services | Cabometyx Drug, Oncology | 2019 | |
| 2019-03-25 | Clovis Oncology, Inc. | $12 | Food and Beverage | In-kind items and services | Rubraca Drug, Oncology | 2019 | |
| 2019-02-27 | AstraZeneca Pharmaceuticals LP | $104 | Food and Beverage | In-kind items and services | IMFINZI Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-02-21 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-01-21 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-04-07 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $1,262 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2025 |
| 2025-02-17 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $4,800 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2025 |
| 2024-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $719 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $3,095 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $54,999 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $6,518 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2024 |
| 2023-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $274,640 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $23,704 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $3,112 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $3,586 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $6,175 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2023 |
| 2023-01-25 | SEAGEN INC. | Allegheny-Singer Research Institute | $3,500 | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2023 |
| 2022-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $15,040 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $2,608 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $81,805 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $2,706 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $546,270 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $5,078 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $121,504 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $5,762 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2022 |
| 2022-12-14 | SEAGEN INC. | Allegheny-Singer Research Institute | $500 | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2022 |
| 2022-09-28 | SEAGEN INC. | Allegheny-Singer Research Institute | $1,000 | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2022 |
| 2022-08-30 | Eli Lilly and Company | ALLEGHENY SINGER RESEARCH INSTITUTE | $1,000 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTR | 2022 |
| 2022-07-15 | Novartis Pharmaceuticals Corporation | ALLEGHENY SINGER RESEARCH INSTITUTE | $12,650 | A SINGLE ARM PHASE II STUDY TO EVALUATE REOCCURRENCE - FREE SURVIVAL IN CTDNA-POSITIVE STAGE III COLON CANCER PATIENTS W | 2022 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | Allegheny-Singer Research Institute | $316 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY SINGER RESEARCH INSTITUTE | $10,805 | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $280,144 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $12,029 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $110,746 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $8,288 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | Allegheny-Singer Research Institute | $248 | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) i | 2021 |
| 2021-11-17 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $118,947 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2021 |
| 2021-09-03 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $51,334 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2021 |
| 2021-08-25 | SEAGEN INC. | Allegheny-Singer Research Institute | $24,900 | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2021 |
| 2021-08-23 | SEAGEN INC. | Allegheny-Singer Research Institute | $16,406 | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2021 |
| 2021-08-23 | SEAGEN INC. | Allegheny-Singer Research Institute | $32,991 | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2021 |
| 2021-08-23 | SEAGEN INC. | Allegheny-Singer Research Institute | $7,791 | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2021 |
| 2021-06-16 | AstraZeneca Pharmaceuticals LP | Allegheny-Singer Research Institute | $5,000 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2021 |
| 2021-05-03 | Eli Lilly and Company | ALLEGHENY SINGER RESEARCH INSTITUTE | $500 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTR | 2021 |
| 2021-03-19 | BeiGene, Ltd. | ALLEGHENY SINGER RESEARCH INSTITUTE | $1,500 | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A3 | 2021 |
| 2021-02-09 | E.R. Squibb & Sons, L.L.C. | Allegheny-singer Research Institute (asri) | $1,800 | A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cance | 2021 |
| 2021-02-04 | AstraZeneca Pharmaceuticals LP | Allegheny-Singer Research Institute | $3,000 | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) i | 2021 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | Copernicus Group Inc | $785 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | Allegheny-Singer Research Institute | $10,308 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | Allegheny-Singer Research Institute | $1,037 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2020 |
| 2020-12-14 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $39,083 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $38 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $72 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $8 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $8 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $47 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $36 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $7 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $99 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $106 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $20 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $24 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $0 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $114 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $117 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $20 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $21 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $23 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $5 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $24 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $31 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $31 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $36 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-11-30 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $26,055 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-11-20 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $600 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-11-19 | BeiGene, Ltd. | ALLEGHENY SINGER RESEARCH INSTITUTE | $100 | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A3 | 2020 |
| 2020-11-19 | BeiGene, Ltd. | ALLEGHENY SINGER RESEARCH INSTITUTE | $1,000 | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A3 | 2020 |
| 2020-11-13 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $1,900 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-10-19 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $32,569 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-10-15 | BeiGene, Ltd. | ALLEGHENY SINGER RESEARCH INSTITUTE | $750 | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A3 | 2020 |
| 2020-09-28 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $750 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-09-28 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $2,814 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-09-28 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $4,240 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-09-23 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $3,800 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-09-09 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $750 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $26,055 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $24 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $23 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $34 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $35 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $31 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $2 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $1 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-10 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $27 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-03 | Merck Sharp & Dohme LLC | ALLEGHENY SINGER RESEARCH INSTITUTE | $475 | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva | 2020 |
| 2020-08-03 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $26,055 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-08-03 | Merck Sharp & Dohme LLC | ALLEGHENY SINGER RESEARCH INSTITUTE | $1,207 | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva | 2020 |
| 2020-07-31 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $2,032 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-07-15 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $6,122 | A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab P | 2020 |
| 2020-07-15 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $250 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-07-15 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $1,500 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $24 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $0 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $1 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-07-09 | Merck Sharp & Dohme LLC | ALLEGHENY GENERAL HOSPITAL | $19 | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Denver, NC, county Lincoln County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Denver, NC | County Lincoln County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 2,497 | 92,716 | 10,730,404 |
| Population, 2020 census P1 | 2,697 | 86,810 | 10,439,388 |
| Median age B01002 | 38.9 | 44.4 | 39.1 |
| Under 18 B01001 | 20.4% | 20.6% | 21.8% |
| 65 and over B01001 | 11.7% | 19.5% | 17.2% |
| Households B11001 | 1,122 | 36,811 | 4,282,345 |
| Foreign born B05002 | 0.9% | 5.5% | 9.1% |
| Median household income B19013 | $65,721 | $80,016 | $72,388 |
| Median family income B19113 | $82,898 | $95,817 | $90,290 |
| Per capita income B19301 | $37,980 | $44,098 | $41,385 |
| Poverty rate B17001 | 6.0% | 11.2% | 13.0% |
| Unemployment rate B23025 | 2.6% | 3.3% | 4.7% |
| Civilian labor force B23025 | 1,464 | 46,238 | 5,336,863 |
| Mean commute (minutes) B08013 | 29.4 | 29.3 | 25.1 |
| Bachelor's degree or higher B15003 | 43.6% | 28.3% | 35.7% |
| Housing units B25001 | 1,170 | 39,504 | 4,895,668 |
| Owner-occupied B25003 | 55.2% | 78.9% | 66.6% |
| Renters B25003 | 44.8% | 21.1% | 33.4% |
| Median home value B25077 | $296,300 | $321,000 | $288,900 |
| Median gross rent B25064 | $869 | $1,015 | $1,228 |
| White, not Hispanic B03002 | 86.7% | 82.0% | 60.0% |
| Black B03002 | 0.0% | 5.9% | 20.0% |
| Hispanic or Latino B03002 | 0.3% | 8.1% | 11.3% |
| Asian B03002 | 0.0% | 0.8% | 3.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, NC.
Comments